Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autoliv, Inc. stock logo
ALV
Autoliv
$125.35
+0.1%		$121.02
$99.16
▼
$132.17
$9.18B1.36520,829 shs559,424 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.94
$11.21
$6.28
▼
$12.48
$4.06B-0.17139,209 shs140,964 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autoliv, Inc. stock logo
ALV
Autoliv
0.00%+2.55%+1.90%-2.36%+0.63%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%+5.76%+3.65%+29.50%+31.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autoliv, Inc. stock logo
ALV
Autoliv
$125.35
+0.1%		$121.02
$99.16
▼
$132.17
$9.18B1.36520,829 shs559,424 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$11.94
$11.21
$6.28
▼
$12.48
$4.06B-0.17139,209 shs140,964 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autoliv, Inc. stock logo
ALV
Autoliv
0.00%+2.55%+1.90%-2.36%+0.63%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%+5.76%+3.65%+29.50%+31.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autoliv, Inc. stock logo
ALV
Autoliv
2.62
Moderate Buy$135.938.44% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.86
Moderate Buy$20.4070.85% Upside

Current Analyst Ratings Breakdown

Latest TLX, MUV2, WUW, and ALV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$20.00
8/21/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Hold (C-)
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/20/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$22.00
7/20/2026
Autoliv, Inc. stock logo
ALV
Autoliv
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Buy (B-)
7/20/2026
Autoliv, Inc. stock logo
ALV
Autoliv
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$148.00 ➝ $147.00
7/20/2026
Autoliv, Inc. stock logo
ALV
Autoliv
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$150.00 ➝ $148.00
7/17/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
7/17/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform
7/16/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$18.00
7/13/2026
Autoliv, Inc. stock logo
ALV
Autoliv
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$138.00 ➝ $148.00
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autoliv, Inc. stock logo
ALV
Autoliv
$10.82B0.85$15.36 per share8.16$33.99 per share3.69
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$803.79M5.05$0.04 per share283.18$1.23 per share9.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autoliv, Inc. stock logo
ALV
Autoliv
$735M$8.4914.7610.801.005.79%29.36%8.86%10/23/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A199.00N/AN/AN/AN/AN/A

Latest TLX, MUV2, WUW, and ALV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/17/2026Q2 2026
Autoliv, Inc. stock logo
ALV
Autoliv
$2.46$2.43-$0.03$1.35$2.77 billion$2.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Autoliv, Inc. stock logo
ALV
Autoliv
$3.482.78%+20.27%40.99%1 Years
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A

Latest TLX, MUV2, WUW, and ALV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/13/2026
Autoliv, Inc. stock logo
ALV
Autoliv
quarterly$0.872.85%8/28/20268/28/20269/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autoliv, Inc. stock logo
ALV
Autoliv
0.67
1.03
0.79
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85

Institutional Ownership

CompanyInstitutional Ownership
Autoliv, Inc. stock logo
ALV
Autoliv
69.57%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Autoliv, Inc. stock logo
ALV
Autoliv
0.34%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Autoliv, Inc. stock logo
ALV
Autoliv
64,30073.24 million72.99 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.78 millionN/AN/A

Recent News About These Companies

TLX stock clocks 5% gain this week ahead of FDA decision on brain cancer imaging agent
September 4 at 7:44 PM  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/tlx-stock-clocks-5-gain-this-week-ahead-of-fda-decision-on-brain-cancer-imaging-agent/ar-AA2bAHHK
Telix Pharmaceuticals Limited (TLX)
September 4 at 9:42 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/TLX/news/
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's What Happened
September 4 at 4:00 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003200
HC Wainwright Reaffirms "Buy" Rating for Telix Pharmaceuticals (NASDAQ:TLX)
September 4 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31001694
Telix shares are up 98%: Is there more upside to come?
September 3, 2026  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/telix-shares-are-up-98-is-there-more-upside-to-come/ar-AA2bsMN7
Telix Pharmaceuticals Limited (NASDAQ:TLX) Given Average Recommendation of "Moderate Buy" by Brokerages
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000143
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Recommendation of "Moderate Buy" from Analysts
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-telix-pharmaceuticals-limited-nasdaq-tlx-receives-average-recommendation-of-moderate-buy-from-analysts-2026-09-03/
Telix Pharmaceuticals shares rise 5.3% as analyst highlights BiPASS trial and FDA pathway
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/telix-pharmaceuticals-shares-rise-53-as-analyst-highlights-bipass-trial-and-fda-pathway/ar-AA2bqKRm
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - What's Next?
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-shares-gap-up-whats-next-2026-09-02/
Telix Pharmaceuticals' (TLX) Buy Rating Reaffirmed at HC Wainwright
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-telix-pharmaceuticals-tlx-buy-rating-reaffirmed-at-hc-wainwright-2026-09-02/
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354739/0/en/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway.html
Telix Appoints Gill As Board Chairman
September 1, 2026  |  rttnews.comhttps://www.rttnews.com/3687297/telix-appoints-gill-as-board-chairman.aspx
Telix Appoints David Gill as Chair
August 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/31/3353743/0/en/telix-appoints-david-gill-as-chair.html
Telix Pharmaceuticals (NASDAQ:TLX) Stock Price Down 4.5% - Time to Sell?
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-stock-price-down-45-time-to-sell-2026-08-26/
Telix Pharmaceuticals: Execution Is The Name Of The Game Here
August 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4939766-telix-pharmaceuticals-execution-is-the-name-of-the-game-here
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-shares-gap-down-heres-what-happened-2026-08-21/
HotCopper highlights: Zip dominates investor attention as Telix, Liontown and American Tungsten trend
August 21, 2026  |  msn.comhttps://www.msn.com/en-au/money/top-stocks/hotcopper-highlights-zip-dominates-investor-attention-as-telix-liontown-and-american-tungsten-trend/ar-AA2aC3f9
Why were Telix shares just downgraded?
August 20, 2026  |  fool.com.auhttps://www.fool.com.au/2026/08/21/why-were-telix-shares-just-downgraded/
Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M 
August 20, 2026  |  blockonomi.comhttps://blockonomi.com/telix-pharmaceuticals-limited-tlx-stock-ebitda-surges-146-as-revenue-hits-477m/
Telix Pharmaceuticals Limited: Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69361480-telix-pharmaceuticals-limited-telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline-399.htm
Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telix-pharmaceuticals-nasdaqtlx-receives-outperform-rating-from-wedbush-2026-08-20/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Autoliv stock logo

Autoliv NYSE:ALV

$125.35 +0.15 (+0.12%)
As of 09/4/2026 03:58 PM Eastern

Autoliv, Inc., through its subsidiaries, develops, manufactures, and supplies passive safety systems to the automotive industry in Europe, the Americas, China, Japan, and rest of Asia. It offers passive safety systems, including modules and components for frontal-impact airbag protection systems, side-impact airbag protection systems, seatbelts, steering wheels, and inflator technologies. The company also provides mobility safety solutions, such as pedestrian protection, battery cut-off switches, connected safety services, and safety solutions for riders of powered two wheelers. It primarily serves car manufacturers. Autoliv, Inc. was founded in 1953 and is headquartered in Stockholm, Sweden.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$11.94 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas